Bi Timothy M, Daggett Valerie
Department of Bioengineering, University of Washington, Seattle, WA.
Yale J Biol Med. 2018 Sep 21;91(3):247-255. eCollection 2018 Sep.
A major barrier to developing effective treatments and diagnostics for amyloid diseases is the inability of traditional protein structure characterization methods to elucidate the structure of the toxic oligomers that form during amyloidogenesis. Some years ago, our lab "discovered" a novel protein secondary structure in molecular dynamics simulations of multiple unrelated amyloid proteins, which we call α-sheet. We hypothesize that α-sheet plays an important role in amyloid aggregation and oligomer toxicity. De novo monomeric α-sheet peptides designed to be complementary to the structure observed in simulations inhibit amyloid aggregation and toxicity and specifically bind to the toxic oligomeric species in a variety of unrelated mammalian and bacterial amyloid systems associated with a range of diseases. Furthermore, spectroscopic analysis of α-sheet structure, including nuclear magnetic resonance (NMR), circular dichroism (CD), and Fourier-transform infrared spectroscopy (FTIR), correspond well to values predicted for α-sheet. These α-sheet designs are now being tested for their ability to detect and neutralize toxic oligomers in animals and in patient samples, demonstrating the potential of this nonstandard secondary structure as a target for therapeutic and diagnostic agents for amyloid diseases.
为淀粉样疾病开发有效治疗方法和诊断手段的一个主要障碍是,传统蛋白质结构表征方法无法阐明淀粉样蛋白生成过程中形成的有毒寡聚体的结构。几年前,我们实验室在多个不相关淀粉样蛋白的分子动力学模拟中“发现”了一种新型蛋白质二级结构,我们称之为α-折叠。我们推测α-折叠在淀粉样蛋白聚集和寡聚体毒性中起重要作用。设计与模拟中观察到的结构互补的从头单体α-折叠肽可抑制淀粉样蛋白聚集和毒性,并在与一系列疾病相关的各种不相关哺乳动物和细菌淀粉样蛋白系统中特异性结合有毒寡聚体。此外,对α-折叠结构的光谱分析,包括核磁共振(NMR)、圆二色性(CD)和傅里叶变换红外光谱(FTIR),与α-折叠预测值吻合良好。目前正在测试这些α-折叠设计在动物和患者样本中检测和中和有毒寡聚体的能力,这表明这种非标准二级结构作为淀粉样疾病治疗和诊断药物靶点的潜力。